Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

[1]  D. Cunningham,et al.  COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. , 2013 .

[2]  G. Mills,et al.  Targeting the hepatocyte growth factor-cMET axis in cancer therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Rebecca C Fitzgerald,et al.  A systematic approach to therapeutic target selection in oesophago-gastric cancer , 2012, Gut.

[4]  A. Wotherspoon,et al.  A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Joon-Oh Park,et al.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[8]  D. Carbone,et al.  Insulin‐like growth factor‐I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45 , 2011, Cancer.

[9]  D. Cunningham,et al.  Targeting angiogenesis in esophagogastric adenocarcinoma. , 2011, The oncologist.

[10]  Tao Li,et al.  Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer , 2011, PloS one.

[11]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[12]  C. Heldin,et al.  Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer , 2010, BMC Cancer.

[13]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[14]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Jayson,et al.  Biomarkers of angiogenesis and their role in the development of VEGF inhibitors , 2009, British Journal of Cancer.

[16]  Takao Kawabe,et al.  Regulation of the hedgehog signaling by the mitogen‐activated protein kinase cascade in gastric cancer , 2009, Molecular carcinogenesis.

[17]  K. Shim,et al.  The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer , 2009, Gut and liver.

[18]  Su-jin Kim,et al.  Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer , 2008, BMC Cancer.

[19]  G. Basaran,et al.  Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and Prognostic Impact on Survival , 2007, Oncology.

[20]  M. Orditura,et al.  Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients , 2007, Annals of Surgical Oncology.

[21]  Ji-Feng Wu,et al.  Microvessel density is a prognostic marker of human gastric cancer. , 2006, World journal of gastroenterology.

[22]  M. Vieth,et al.  Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Gong,et al.  Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. , 2002, World journal of gastroenterology.

[24]  L. Ellis,et al.  Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.

[25]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[29]  David L. DeMets,et al.  Asymmetric group sequential boundaries for monitoring clinical trials , 1982 .